Insider Shareholders with Direct Ownership of Genelux Corp (GNLX)
This section provides a comprehensive overview of the insiders with direct ownership of Genelux Corp (GNLX). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
GENELUX CORP Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
| 524,501 | 19,000 | 505,501 | 9 |
Aug 01, 2024
Added 7.25%
|
|
|
Qian Zhang
Associate VP, Research |
6,000 | 0 | 139,333 | 1 |
Feb 17, 2023
Added 4.13%
|
| 52,711 | 900 | 52,711 | 4 |
Aug 01, 2024
Added 42.86%
|
|
| 52,001 | 0 | 52,001 | 4 |
Aug 01, 2024
Added 43.19%
|
|
|
Thomas Zindrick
President and CEO |
57,584 | 8,349 | 50,207 | 4 |
Mar 14, 2024
Added 34.35%
|
| 58,251 | 10,730 | 47,521 | 6 |
Sep 11, 2024
Reduced 3.51%
|
|
|
Lourie S. Zak
Chief Financial Officer |
36,322 | 0 | 31,250 | 3 |
May 29, 2024
Added 50.0%
|
|
Joseph Cappello
VP, Pharmaceutical Development |
24,218 | 3,265 | 20,953 | 4 |
Mar 14, 2024
Added 35.55%
|
|
Sean Ryder
General Counsel |
33,106 | 15,824 | 19,388 | 8 |
Jun 24, 2024
Reduced 22.09%
|
|
Caroline Jewett
Head of Quality |
24,755 | 5,476 | 16,174 | 5 |
Jun 24, 2024
Reduced 23.47%
|
|
Ralph Smalling
Head of Regulatory |
13,973 | 935 | 13,315 | 5 |
May 29, 2024
Added 8.58%
|
|
Tony Yu
VP, Clinical Trial Operations |
58,718 | 197,849 | 10,869 | 23 |
Jun 24, 2024
Reduced 38.66%
|
|
Gabe Woodward
Director |
4,186 | 0 | 4,186 | 2 |
Feb 17, 2023
Added 19.28%
|
|
Doug Samuelson
Vice President, Finance |
3,600 | 1,297 | 2,303 | 2 |
Aug 18, 2023
Reduced 36.03%
|
| 0 | 32,167 | 0 | 1 |
Sep 19, 2023
Reduced 100.0%
|